Beam Therapeutics (BEAM) Non-Current Deffered Revenue (2020 - 2025)

Beam Therapeutics (BEAM) has reported Non-Current Deffered Revenue for 6 consecutive years, with $10.2 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Non-Current Deffered Revenue fell 82.43% year-over-year to $10.2 million; the TTM figure through Sep 2025 stood at $10.2 million (down 82.43% YoY), while the FY2024 annual figure was $33.2 million, down 69.77% from the prior year.
• Non-Current Deffered Revenue retreated to $10.2 million in Q3 2025 per BEAM's latest filing, from $20.3 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $262.3 million in Q4 2021 and bottomed at $10.2 million in Q3 2025.
• Historically, Non-Current Deffered Revenue has averaged $115.7 million across 5 years, with a median of $104.7 million in 2023.
• Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue soared 66474.37% — and 2025, when it plunged 82.43%.
• Beam Therapeutics' Non-Current Deffered Revenue stood at $262.3 million in 2021, then retreated by 22.92% to $202.2 million in 2022, then plunged by 45.65% to $109.9 million in 2023, then sank by 69.77% to $33.2 million in 2024, then slumped by 69.41% to $10.2 million in 2025.
• Business Quant data shows BEAM's Non-Current Deffered Revenue at $10.2 million in Q3 2025, $20.3 million in Q2 2025, and $49.4 million in Q1 2025.